Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.48), FiscalAI reports. The firm had revenue of $196.40 million during the quarter, compared to analysts’ expectations of $195.16 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%.

Here are the key takeaways from Supernus Pharmaceuticals’ conference call:

• Supernus reported a record full‑year revenue of $719 million in 2025, with its four growth products accounting for ~76% of Q4 revenue, signaling a successful transition from legacy products.
• ONAPGO received FDA approval and finished its first year with $17.3 million in net sales (Q4: $8.9M); the company resumed new patient starts and guided to $45M–$70M of ONAPGO net sales for 2026.
• The Sage acquisition and related integration raised costs materially—combined R&D and SG&A rose to $591.8 million for 2025, driving a GAAP net loss of $38.6 million and reducing cash to $309 million, which increases near‑term profitability and cash‑burn scrutiny despite no debt.
• R&D progress includes a Phase IIb start for SPN‑820, ongoing Phase IIb for SPN‑817, and a planned Phase I for SPN‑443 in H2 2026; the company will retain select Sage assets and seek partners for others, with key clinical readouts expected in 2027.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded up $2.61 on Tuesday, reaching $53.30. The company’s stock had a trading volume of 2,158,157 shares, compared to its average volume of 727,006. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $57.65. The business’s 50-day moving average price is $50.24 and its two-hundred day moving average price is $48.01. The firm has a market cap of $3.06 billion, a PE ratio of -156.76, a PEG ratio of 0.64 and a beta of 0.71.

Analysts Set New Price Targets

Several analysts have commented on SUPN shares. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price for the company. Zacks Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Finally, Stifel Nicolaus upped their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $61.60.

Key Headlines Impacting Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Record Q4 and full‑year 2025 revenue growth led by its four growth products (Q4 revenue $211.6M; FY revenue $719.0M; combined growth-product sales +45% Q/Q and +40% Y/Y), which supports the bull case on durable organic sales expansion. Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Wall Street support and price targets remain constructive (multiple buy/overweight ratings and median target near $63), which can lift sentiment into upcoming conferences and offset the EPS miss. Supernus Pharmaceuticals Announces Participation in March Investor Conferences
• Neutral Sentiment: Management will present at multiple March investor conferences (TD Cowen, Jefferies, Barclays). These roadshow events increase visibility and could provide new guidance or pipeline updates that move the stock, but have no immediate financial impact. Supernus Pharmaceuticals to Participate in March Investor Conferences
• Neutral Sentiment: Total revenue narrowly exceeded consensus ($196.4M reported vs. ~$195.2M estimate), which is marginally positive but overshadowed by the EPS miss — investors may focus on revenue mix and margins in conference calls. Q4/FY2025 Press Release
• Negative Sentiment: Q4 EPS missed materially (reported -$0.07 vs. $0.41 consensus), producing near-term headline risk and questions about margin pressure or one-time items behind the loss. Q4/FY2025 Press Release
• Negative Sentiment: Board approved new equity-based incentives that increase executive pay — could imply dilution risk or governance concerns for some investors. Supernus boosts executive pay with new equity incentives
• Negative Sentiment: Insider selling disclosed (Director Bethany Sensenig sold 4,475 shares; regulatory filings show other insider sales in recent months), which can concern investors about insider confidence or trigger short‑term pressure. SEC Form 4 — Insider Sale

Insider Activity

In related news, SVP Frank Mottola sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bethany Sensenig sold 4,475 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 25,185 shares of company stock worth $1,268,022 in the last 90 days. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $21,908,000. Woodline Partners LP grew its holdings in shares of Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Bank of America Corp DE increased its position in shares of Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after acquiring an additional 338,584 shares during the last quarter. Morgan Stanley raised its holdings in Supernus Pharmaceuticals by 42.9% during the fourth quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock worth $53,650,000 after acquiring an additional 324,154 shares in the last quarter. Finally, UBS Group AG boosted its position in Supernus Pharmaceuticals by 137.6% during the third quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after purchasing an additional 312,775 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.